US · Healthcare · Biotechnology
EPS came in at -0.84 against a street estimate of -1.21 — a beat of 30.6%.
Analysts rate Rapport Therapeutics, Inc. Common Stock a strong buy (16 buy, 0 hold, 0 sell out of 16) with an average price target of $68.29.
| Fund | Stake |
|---|---|
| FMR Inc | 14.95% |
| TRV GP V, LLC | 13.09% |
| ARCH VENTURE CORP | 7.77% |
| Capital Research & Mgmt Co - Division 3 | 6.09% |
| The Goldman Sachs Group Inc | 6.07% |
| BlackRock Inc | 5.63% |
| Cormorant Asset Management, LLC | 5.54% |
| Sofinnova Ventures | 3.97% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Rapport Therapeutics reported a net loss of $116.707 million for the nine months ended September 30, 2026, compared with $77.720 m | 2026-11-04 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 net loss was $40.2 million, versus $26.9 million in the prior-year period. • Revenue was not reported; the com | 2026-11-04 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Rapport Therapeutics, Inc. entered into a First Supplemental Indenture dated October 30, 2026 with U.S. Bank Trust Company, Nation | 2026-10-30 |
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • Rapport Therapeutics announced positive topline results from a Phase 2 trial of RAP-219 in adults with acute mania associated with | 2026-10-20 |
| Quarterly report · Q2 2026 RAPPORT THERAPEUTICS, INC. – 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash Position: $63.6 million in cash and cash equivalents plus $372.5 million | 2026-08-05 |
| Results announced · Q3 2026 RAPPORT THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Net loss for Q2 2026: $56.6 million (versus $26.7 million in Q2 2025) • Cash posit | 2026-08-05 |
| Shareholder vote results · Q2 2026 RAPPORT THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Outstanding shares: 47,807,623 common shares as of April 14, 2026 (record date) • Stock | 2026-06-10 |
| Quarterly report · Q1 2026 RAPPORT THERAPEUTICS, INC. - 10-Q SUMMARY Q1 2026 (Quarter Ended March 31, 2026) --- HEADLINE NUMBERS • Cash and Short-term Investments: $476.8 mil | 2026-05-07 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Rapport Therapeutics, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.